July 2026—Among its many peculiarities, medicine dwells in interstitial spaces—between seeing a problem and addressing it; between the (in)actions of one specialty and another; between practice and practice guidelines; between overtreatment and targeted treatment; between widespread access and boutique care.
July 2026—When Neha Gupta, MD, attended a fellowship fair early in her second year of residency, she was caught off guard by the number of programs already accepting applications from her peers. It was only March, and she had been told she could apply for her fellowship in late summer.
July 2026—An International Association for the Study of Lung Cancer panel provided recommendations in 2020 on how to process lung cancer resection specimens and define pathologic response after neoadjuvant therapy. They were intended as guidance for clinical trials but offered as a suggestion for good clinical practice.
July 2026—This discussion is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert to spotlight a company and a customer for their laboratory solutions and work. He spoke on July 21, 2026 with Nick Fingland, PhD, PMP, Senior Director R&D Operations and Science, BD, and Chris Farnsworth, PhD D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Watch the full conversation:
This roundtable discussion is sponsored by BD.
CAP TODAY RECOMMENDS
Discover how Epredia Lab 360 transforms modern pathology workflows with a fully integrated solution combining instrumentation, consumables, and services. Learn More
July 2026—There’s an important election coming up, and it’s not the one you’ve been hearing about on the news. Voting will begin soon for new members of the CAP’s Board of Governors, and I urge you to take part.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: chemistry/immunoassay analyzers for mid- and high-volume labs
July 2026—This discussion is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert to spotlight a company and a customer for their laboratory solutions and work. He spoke on July 21, 2026 with Nick Fingland, PhD, PMP, Senior Director R&D Operations and Science, BD, and Chris Farnsworth, PhD D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Watch the full conversation:
This roundtable discussion is sponsored by BD.
May 2026—When it comes to cancer mutations, there are big fish in little ponds, and little fish in big ponds, and big fish in big ponds, and little fish in little ponds. The ESR1 mutation and its emergence in advanced breast cancer is still deciding what stripe of fish it is—or rather, breast specialists, researchers, and the FDA are in the midst of figuring out potentially important uses …
May 2026—Two years after the Food and Drug Administration approved the first HPV self-collection devices, physicians and cervical cancer prevention advocates are debating the best use for the new screening option.
May 2026—In the laboratory general accreditation checklist in the 2025 edition, released last December, is new emphasis on a prospective risk assessment process in the laboratory’s quality management …
MARKETPLACE
July 2026—Tempus AI has launched the ArteraAI Prostate test (mHSPC) for clinical use. The test uses multimodal artificial intelligence to provide insights for personalized care for patients with metastatic hormone-sensitive prostate cancer.